Biomarker detection using TruSight® Oncology 500

/
Melanoma is the third most common cancer in Australia, with an average of one person diagnosed every 30 minutes. One treatment approach for melanoma is through immunotherapy – stimulating the patient’s immune system to recognise and destroy the cancerous cells. Unfortunately, immunotherapy is only effective in approximately 50% of advanced melanoma cases.1

The Personalised Immunotherapy Platform (PIP) PREDICT clinical trial led by Associate Professor James Wilmott at the Melanoma Institute Australia, is aiming to predict which patients with advanced melanoma will respond to immunotherapy prior to treatment. By identifying these patients, overall clinical care is improved, and alternative therapies can be adopted sooner in patients predicted to not benefit from immunotherapy. AGRF has supported the PIP-PREDICT clinical trial through developing a rapid sample-to-data workflow process to provide biomarker data from the Illumina TruSight Oncology 500 (TSO500) assay. AGRF continues to support the clinical trial by rapidly delivering sequencing and bioinformatic data, used for the predictive models to improve patient care.

AGRF has supported the PIP-PREDICT clinical trial through developing a rapid sample-to-data workflow process to provide biomarker data from the Illumina TruSight Oncology 500 (TSO500) assay. AGRF continues to support the clinical trial by rapidly delivering sequencing and bioinformatic data, used for the predictive models to improve patient care.

References

1 Melanoma Institute Australia (2024), Melanoma Facts, Available at https://melanoma.org.au/about-melanoma/melanoma-facts/, Accessed 15 October 2024.